Jefferies upgraded ALX Oncology to Buy from Hold with a price target of $18, up from $8. The company has three major randomized controlled Phase II studies in 2024 which could work and stock is “very cheap” at a $100M enterprise value, the analyst tells investors in a research note. The firm says 2024 could be a potential “come back year” for ALX with “significant catalysts.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology price target lowered to $10 from $11 at Stifel
- ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- ALX Oncology reports Q3 EPS ($1.24), consensus (87c)
- ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
